| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$1 ) |
| | 2026 | 2023 | NOSTOPHARMA LLC | 5 GREENLANE CT | POTOMAC | MD | 20854-3508 | MONTGOMERY | USA | R43TR004574 | Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease | 000 | 1 | NIH | 11/18/2025 | -$1 |
|
| Issue Date FY: 2025 ( Subtotal = $407,792 ) |
| | 2025 | 2025 | NOSTOPHARMA LLC | 5 GREENLANE CT | POTOMAC | MD | 20854-3508 | MONTGOMERY | USA | R21TR005159 | Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva | 001 | 1 | NIH | 8/12/2025 | $0 |
| | 2025 | 2025 | NOSTOPHARMA LLC | 5 GREENLANE CT | POTOMAC | MD | 20854-3508 | MONTGOMERY | USA | R21TR005159 | Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva | 000 | 1 | NIH | 7/3/2025 | $407,792 |
|
| Issue Date FY: 2024 ( Subtotal = $44,394 ) |
| | 2024 | 2024 | NOSTOPHARMA LLC | 7600 CODDLE HARBOR LN | POTOMAC | MD | 20854-3251 | MONTGOMERY | USA | R43TR004574 | Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease | 000 | 1 | NIH | 3/1/2024 | $44,394 |
|
| Issue Date FY: 2023 ( Subtotal = $318,796 ) |
| | 2023 | 2023 | NOSTOPHARMA LLC | 7600 CODDLE HARBOR LN | POTOMAC | MD | 20854-3251 | MONTGOMERY | USA | R43TR004574 | Small molecules combination therapy using polypharmacology approach as a novel treatment paradigm for rare bone disease | 000 | 1 | NIH | 8/10/2023 | $318,796 |
|
|
